Blar i NTNU Open på forfatter "Ayuda-Duran, Maria del Pilar"

Viser treff 1-2 av 2

    • Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors 

      Pietarinen, Paavo O; Eide, Christopher A; Ayuda-Duran, Maria del Pilar; Potdar, Swapnil; Kuusanmäki, Heikki; Andersson, Emma I; Mpindi, John P; Pemovska, Tea; Kontro, Mika; Heckman, Caroline A.; Kallioniemi, Olli; Wennerberg, Krister; Hjorth-Hansen, Henrik; Druker, Brian J; Enserink, Jorrit; Tyner, Jeffrey W.; Mustjoki, Satu; Porkka, Kimmo (Peer reviewed; Journal article, 2017)
      Tyrosine kinase inhibitors (TKI) are the mainstay treatment of BCR-ABL1-positive leukemia and virtually all patients with chronic myeloid leukemia in chronic phase (CP CML) respond to TKI therapy. However, there is limited ...

    • Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies 

      Melvold, Katrine; Giliberto, Mariaserena; Karlsen, Linda; Ayuda-Duran, Maria del Pilar; Hanes, Robert; Holien, Toril; Enserink, Jorrit; Brown, Jennifer R.; Tjønnfjord, Geir Erland; Tasken, Kjetil; Skånland, Sigrid Strand (Peer reviewed; Journal article, 2021)
      Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. ...